Genetically-modified Autologous T Cells [EPC]

10160 reported adverse events

Drugs of this class: AXICABTAGENE CILOLEUCEL

These side effects are most commonly reported by patients taking drugs of the Genetically-modified Autologous T Cells [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 4622
1 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 2149
2 NEUROTOXICITY 1381
3 DEATH 1056
4 PYREXIA 906
5 DISEASE PROGRESSION 842
6 NEUTROPENIA 520
7 DIFFUSE LARGE B-CELL LYMPHOMA 403
8 HYPOTENSION 400
9 FEBRILE NEUTROPENIA 308
See all common reactions for Genetically-modified Autologous T Cells [EPC]

Drugs of the Genetically-modified Autologous T Cells [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CAR T-CELL-RELATED ENCEPHALOPATHY SYNDROME 115 0.9274
1 CYTOKINE INCREASED 76 0.5630
2 LYMPHOCYTE ADOPTIVE THERAPY 107 0.3835
3 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 2149 0.3625
4 MALIGNANT GENITOURINARY TRACT NEOPLASM 24 0.3582
5 IMMUNE EFFECTOR CELL-ASSOCIATED HAEMATOTOXICITY 58 0.3333
6 PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA 28 0.2393
7 CYTOKINE RELEASE SYNDROME 4622 0.2302
8 B-CELL APLASIA 46 0.1783
9 IMMUNE EFFECTOR CELL-ASSOCIATED HLH-LIKE SYNDROME 19 0.1258
See all enriched reactions for Genetically-modified Autologous T Cells [EPC]